Key Highlights

● VivoSim signed a seven-figure NAMkind testing deal with a top-10 pharma company.

● The customer was not named.

● VivoSim now expects to beat its fiscal 2027 Revenue growth guidance.

● The stock last closed near $0.12, valuing the company at about $2.4 million.

VivoSim Labs (NASDAQ:VIVS) shares rocketed during Thursday's session after the tiny toxicology-testing company announced a seven-figure agreement with one of the world's ten largest drugmakers.

The contract

VivoSim Labs said it had signed a seven-figure agreement to provide NAMkind toxicology testing to a top-10 global pharmaceutical company, according to the announcement. The company did not name the customer. VivoSim also said it now expects to beat its fiscal 2027 revenue growth guidance, which was already set at a very steep rate.

Shares rocketed in Thursday's trading on November 19, ranking among the biggest gainers in late-morning trading. These were intraday figures rather than closing prices.

A very small company

Scale is essential context here. Before the jump, VivoSim's shares last closed at about $0.12, and the company's Market Value was roughly $2.4 million, according to market data. At that size, a contract worth seven figures is meaningful relative to the whole company, which helps explain the force of the reaction. It also means the stock can swing violently on modest trading volume, in either direction.

Sub-$1 stocks trade with wide price swings, and intraday moves of this kind can reverse quickly. Intraday figures reflect one moment in the session rather than a settled result.

What toxicology testing involves

Before a drug candidate can be tested in people, developers must show that it is reasonably safe, and toxicology studies are a central part of that work. Traditionally, much of that testing has relied on animal studies. VivoSim's NAMkind service is a toxicology testing offering for drug developers. The announcement did not set out the methods involved in detail.

A contract from a top-10 drugmaker therefore carries weight beyond its dollar value for a company of VivoSim's size, because it signals that a major customer is willing to pay for the service. No further details on the scope or duration of the agreement were disclosed.

A sea of red

The surge stood out against a punishing market. The Nasdaq Composite dropped 550.69 points to 23,879.20, its lowest close since April, according to market data. The S&P 500 slid 147.80 points to 7,175.83, a sixth straight loss, while the Dow Jones Industrial Average shed 1,101.11 points to 49,097.06. The Russell 2000 lost 59.20 points, and the S&P SmallCap 600 was the worst of the major indexes. Breadth was dismal, with S&P 500 decliners outnumbering advancers by more than ten to one, according to market tallies.

Stocks had opened higher and held gains through the morning before turning lower around midday, after Anthropic (NASDAQ:ANT)'s record IPO began trading and then faded. Selling accelerated into the close, and fear gauges rose, with the VIX climbing 3.88 points to 28.44.

What to watch

Investors will look for more detail from VivoSim on the agreement, including its timing and how revenue will be recognised, and for an update on how the company now sees its fiscal 2027 growth. Given the share price below $1, the stock is likely to remain prone to large swings. Intraday levels may differ markedly from the close.